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Agorreta, Jackeline, Javier J. Zulueta, Luis M. Montuenga,
and Mercedes Garayoa. Adrenomedullin expression in a rat model
of acute lung injury induced by hypoxia and LPS. Am J Physiol
Lung Cell Mol Physiol 288: L536 –L545, 2005. First published
December 3, 2004; doi:10.1152/ajplung.00314.2004.—Adrenomedullin
(ADM) is upregulated independently by hypoxia and LPS, two key
factors in the pathogenesis of acute lung injury (ALI). This study
evaluates the expression of ADM in ALI using experimental models
combining both stimuli: an in vivo model of rats treated with LPS and
acute normobaric hypoxia (9% O2) and an in vitro model of rat lung
cell lines cultured with LPS and exposed to hypoxia (1% O2). ADM
expression was analyzed by in situ hybridization, Northern blot,
Western blot, and RIA analyses. In the rat lung, combination of
hypoxia and LPS treatments overcomes ADM induction occurring
after each treatment alone. With in situ techniques, the synergistic
effect of both stimuli mainly correlates with ADM expression in
inflammatory cells within blood vessels and, to a lesser extent, to cells
in the lung parenchyma and bronchiolar epithelial cells. In the in vitro
model, hypoxia and hypoxia LPS treatments caused a similar strong
induction of ADM expression and secretion in epithelial and endo-
thelial cell lines. In alveolar macrophages, however, LPS-induced
ADM expression and secretion were further increased by the concom-
itant exposure to hypoxia, thus paralleling the in vivo response. In
conclusion, ADM expression is highly induced in a variety of key
lung cell types in this rat model of ALI by combination of hypoxia and
LPS, suggesting an essential role for this mediator in this syndrome.
acute respiratory distress syndrome; endotoxin; alveolar macro-
phages; endothelial cells; type II pneumocytes
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS), the most severe
expression of acute lung injury (ALI), is characterized by
increased microvascular permeability, severe hypoxemia, and
diffuse pulmonary infiltrates (2). Although there are many
clinical disorders associated with the development of ARDS,
sepsis is the most common cause of this syndrome. ALI/ARDS
represent important clinical entities with mortality rates of
40–50% (30). A recent study estimates an incidence for sepsis-
associated ARDS of 45–63 cases per 105 persons per year in
the USA (10).
Even though LPS treatment induces hypoxemia (via lung
injury), classical rodent models of ALI in which large doses of
LPS are administered result in higher levels of circulating
cytokines than those found in patients with sepsis (14); the
animals die from “cytokine storm,” often not accurately re-
flecting clinical developments in human ALI (32). As noted by
a National Heart, Lung, and Blood Institute working group on
ALI (25), two-hit animal models might better reflect actual
conditions present in patients with ALI. Taking into account
that hypoxia and endotoxin are the main factors involved in
this syndrome (40), we have developed in vivo and in vitro rat
models of ALI combining acute normobaric hypoxia and LPS
insult (1).
Several cytokines, such as IL-1, -6, -8, -10, and TNF- (40),
and other mediators, such as nitric oxide (NO) (1), have been
found to play a crucial role in the orchestration of the inflam-
matory response associated with ALI. Adrenomedullin (ADM)
is a multifunctional regulatory peptide, and its numerous bio-
logical actions support an integrator role in the cellular re-
sponse to inflammation (7). ADM was originally isolated from
a human pheochromocytoma (16) and belongs to the calcitonin
family, which includes calcitonin gene-related peptide and
amylin. It was initially described for its hypotensive activity
and has since been implicated in diverse physiological func-
tions that include bronchodilation, antimicrobial activity, mod-
ulation of central brain function, cell growth regulation, sur-
vival from apoptosis, and induction of angiogenesis (20). ADM
is expressed in a wide variety of organs, including adult and
fetal lung, and in several types of cancer also comprising lung
cancer (8, 22). Hypoxic conditions, most proinflammatory
cytokines, and LPS upregulate ADM basal expression in cul-
tured cells (8, 26) and in many organs such as lung, heart, and
liver (12, 34). Furthermore, ADM plasma levels are elevated in
patients with lung cancer, asthma, sepsis, chronic obstructive
pulmonary disease, and the systemic inflammatory response
syndrome (SIRS) (20). Together, these premises suggest that
ADM may also play a role in the development of ALI. In an
attempt to investigate this hypothesis, as well as to study the
effect of hypoxia as an added cofactor to LPS treatment in
ALI-reproducing conditions, we have studied the expression of
ADM in in vivo and in vitro models of rat ALI. ADM
expression has been analyzed by Northern blot, RT-PCR, in
situ hybridization (ISH), Western blot, and RIA techniques.
MATERIAL AND METHODS
Animals and Treatments
The protocol followed was similar to that applied previously (1).
Female 7-wk-old Fischer Harlan rats, weighing 125–200 g, were
intraperitoneally injected with saline (200 l) or LPS (0.1 mg/kg
Escherichia coli O111:B4, phenol extract; Sigma, St. Louis, MO) and
immediately exposed to normoxia (room air, 21.8°C, and relative
humidity of 40%; both parameters monitored by datalogger device
Tinytag Ultra; Meaco Europa, Ijzendoorn, Netherlands) or normo-
baric hypoxia (9% O2): rats were placed in a 300  350  600-mm
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Plexiglas chamber specially designed for this project (Martı´nez I´n˜igo,
Pamplona, Spain) at 22.1°C, relative humidity of 50.2%, and gassed
with a mixture of 9% O2-91% N2 at a constant flow throughout the
experiment. Oxygen concentration in the chamber was continuously
monitored with a microPac oxygen sensor (Drager Sicherheitstech-
nik). Four groups resulted from these experimental conditions: 1)
normoxia group (control): rats subjected to normoxia  saline, 2)
hypoxia group: hypoxia  saline, 3) LPS group: normoxia  LPS,
and 4) hypoxia  LPS group. Rats were killed by cervical dislocation
after 3, 6, 12, or 24 h of treatment. At each time point, four rats were
examined in each group (n  64). In the hypoxia  LPS group, all
rats survived after 3 or 6 h of exposure; however, the survival rate
after 12 h was 80%, and the treatment was 100% lethal after 24 h. The
study protocol was approved by the University of Navarra Animal
Care and Use Committee (no. 002/99) and conforms to National
Institutes of Health guidelines. The lungs were excised, and the left
lobes were fixed in buffered formalin for 24 h, dehydrated, and
embedded in paraffin. The correspondent right lobes were divided into
two portions and frozen in liquid nitrogen for subsequent protein or
RNA analyses.
Vascular Permeability to Protein
Extravasation of intravascular protein was measured with FITC-
labeled BSA as an estimate parameter of vascular permeability (35).
In brief, four animals per group (n  16) were injected with 7 mg/kg
of FITC-BSA in 0.1 M phosphate buffer (PB), pH 7.6, in one of the
caudal veins before exposure to each treatment for 6 h. Animals were
deeply anesthetized with an intraperitoneally injected mixture of
ketamine (80 mg/kg) and xylazine (15 mg/kg), the thoracic cavity was
opened, and 1 ml of blood was obtained by cardiac puncture and
adequately reserved for subsequent serum extraction (centrifugation at
1,430 g at 4°C for 30 min). After perfusion of the pulmonary
circulation with PB rinsing solution, the lungs were harvested. The
accessory lobe was fixed in 4% buffered formalin for 24 h, dehy-
drated, and embedded in paraffin; the rest of the lung was weighed,
encased in aluminum foil, and frozen in liquid nitrogen. Immunohis-
tochemical techniques for FITC were applied on 4-m-thick paraffin
sections of lung tissue. After dewaxing, endogenous peroxidase was
inactivated by treatment with 3% hydrogen peroxide for 15 min,
nonspecific background was blocked with normal goat serum (1:20)
for 30 min, and the sections were incubated overnight at 4°C with the
primary monoclonal antibody anti-FITC (Dako, High Wycombe, UK)
at a 1:100 dilution. The sections were revealed with the EnVision
system (Dako) and were subsequently counterstained with hematox-
ylin, dehydrated, and mounted in distyrene plasticizer xilene mount-
ing medium (BDH, Poole, UK). On the other hand, frozen lungs were
thawed and homogenized in five volumes of PB with a Polytron
homogenizer (Kinematica, Steinhofhalde, Switzerland). The homog-
enate was clarified by centrifugation, and the final protein concentra-
tion was determined (BCA kit; Pierce, Rockford, IL). FITC-derived
fluorescence (excitation wavelength, 488 nm; emission wavelength,
520 nm) was detected using a Polastar Galaxy fluorometer (BMBH
Labtechnologies, Offenburg, Germany). The number of fluorescence
units present in the supernatant per milligram of protein was calcu-
lated both for lung homogenates and serum. These values were
transformed with a standard curve obtained by measuring the fluo-
rescence intensity of different dilutions of FITC-BSA in PB and then
plotting the amount of FITC-BSA against the number of fluorescence
units as a graph (35). The vascular permeability index was determined
according to the following ratio expressed as percentage: (ng
FITC/mg protein) lung/(ng FITC/mg protein) serum.
Cell Lines and Exposures
Cell lines in this study were selected to represent the major cell
types occurring in the lung. Normal rat lung type II epithelial cells
(CCL-149), normal rat alveolar macrophages (CRL-2192), and rat
pulmonary microvascular endothelial cells (RPMVEC) were used.
CCL-149 and CRL-2192 were purchased from the American Type
Tissue Collection (Manassas, VA). RPMVEC were a gift from Dr.
Una Ryan (Avant Immunotherapeutics, Needham, MA).
Cell lines were cultured in their specific culturing medium (F-12K
medium for CCL-149 and CRL-2192, and RPMI 1640 for RPMVEC)
supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin,
and 100 g/ml streptomycin (all tissue culture reagents purchased
from GIBCO BRL-Invitrogen, Barcelona, Spain). Fresh medium was
added 12 h before each experiment.
Treatments in vitro tried to reproduce those used in the in vivo
model of rats inhaling 9% O2. Using the alveolar gas equation and
assuming that the respiratory quotient and PaCO2 are similar in rodents
and humans (17), we find that a 9% FIO2 results in an alveolar partial
pressure of O2 (PaO2) of 15 mmHg. To achieve this PaO2, the
concentration of O2 at a barometric pressure of 760 mmHg should
be 1–2%.
Cell cultures were exposed to 20% O2, 5% CO2, 75% N2 (nor-
moxia) or were placed in a humidified airtight incubation chamber
(Billups-Rothenberg, Del Mar, CA) and gassed with 1% O2, 5% CO2,
94% N2 (hypoxia). We added LPS (100 ng/ml) to the cell culture
medium just before initiating exposure to normoxia or hypoxia.
Similarly to the in vivo model, four experimental groups of cells
resulted from combination of these treatments: 1) normoxia, 2) hyp-
oxia, 3) LPS, and 4) hypoxia  LPS. Cells were exposed to each
treatment for 0.5, 1, 3, 6, 12, or 24 h. Immediately after the treatment,
the conditioned media were recovered, and total RNA or protein was
extracted.
Inhibitor Studies
To test whether ADM was being degraded in the culture medium
from the alveolar macrophages cell line (CRL-2192), two additional
experiments with protease inhibitor agents (5 mM EDTA and 0.5 mM
1,10 phenanthroline, Sigma) were carried out: 1) conditioned media
from macrophages exposed to each treatment were incubated with
exogenously added ADM (1.28 ng/ml) for 24 h at 37°C with or
without each inhibitor; 2) 1,10 phenanthroline was added to CRL-
2192 cells subjected to a 24-h treatment. Both protease inhibitors were
chosen because of their ability to prevent ADM degradation (19).
Northern Blot
Northern blot was performed as previously described (8) with
slight modifications. Samples of 15 g of total RNA were separated
in 1% agarose gels containing 2.2 M formaldehyde. RNA was then
transferred by capillarity to nitrocellulose membranes (Schleicher &
Schuell, Keene, NH), and blots were subjected to UV crosslinking at
120 J/cm2. The rat ADM cDNA probe used in this study was kindly
donated by Dr. Alfredo Martı´nez (23). cDNA templates were labeled
with [-32P]dCTP (3,000 Ci/mmol; Amersham Pharmacia Biotech,
Buckinghamshire, UK) by random priming, and unincorporated nu-
cleotides were removed using Probe-Quant G-50 Micro columns
(Amersham Pharmacia Biotech). Hybridization was carried out over-
night at 42°C in a hybridization buffer containing 40% formamide.
Autoradiographic signal was detected using XAR Film (Kodak, Roch-
ester, NY). Densitometric analysis of ADM mRNA expression was
expressed as the ratio of ADM to ribosomal protein S9 mRNA values.
ISH for Rat ADM
The protocol followed was similar to that applied previously (1).
Sections of formalin-fixed rat lung were deparaffinized, rehydrated,
and permeabilized in 0.2% Triton-PBS for 15 min. After a proteinase
K (60 g/ml in 0.1 M Tris-50 mM EDTA, pH 8) digestion at 37°C for
30 min, the process was stopped in 0.1 M glycine-PBS. Tissue was
subsequently acetylated with 0.25% acetic anhydride in 0.1 M trieth-
anolamine, pH 8, washed in diethyl pyrocarbonate-treated H2O, and
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air dried at room temperature. A rat ADM 594-bp RT-PCR product
containing the ADM peptide-coding region [GenBank NM012715:
5-AGCCCACATTCGAGTCAAAC-3 (sense, bp 429–448) and 5-
TTTCCTCGCTAGGTTTTGGA-3 (antisense, bp 1,003–1,022)] was
subcloned into the pCR-II vector (Invitrogen). After plasmid linear-
ization, digoxigenin-labeled riboprobes were synthesized with T7 or
SP6 RNA polymerases with a digoxigenin RNA labeling kit (Roche
Diagnostics, Mannheim, Germany). Hybridization with the antisense
probe (50 ng/l) was performed overnight at 43°C in a moist cham-
ber; hybridization with the sense probe (50 ng/l) in the same
conditions was used as a negative control. After increasingly stringent
washes, the slides were treated with RNase A (20 g/ml) at 37°C for
15 min. Sections were incubated for 2 h with 1:300 antidigoxigenin
antibody labeled with alkaline phosphatase (AP) (Roche Diagnostics).
Nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phos-
phate (Roche Diagnostics) were used to visualize AP activity. Slides
were mounted in 1:1 glycerol-PBS.
RIA for Rat ADM
Cells were seeded in triplicate and subjected to normoxia, hypoxia,
LPS, or hypoxia  LPS treatments for 12, 24, or 48 h. The condi-
tioned media were collected and stored at 20°C with 5 mM EDTA
and a protease inhibitor cocktail. Cellular protein concentration per
plate was determined to verify similar cell protein content so that
ADM in the media could be compared. The concentration of ADM
was measured by RIA analysis according to manufacturer’s instruc-
tions in a commercially available RIA kit for rat ADM (Phoenix
Pharmaceuticals, Belmont, CA). In brief, 0.1 ml of conditioned
medium (or appropriate dilution of standard ADM) was preincubated
for 18 h at 4°C with 0.1 ml of primary antibody against rat ADM.
After that, 0.1 ml of 125I-ADM was added (10,000 cpm), and the
mixture was incubated at 4°C for 18 h. Bound tracer was separated by
precipitation with goat anti-rabbit serum and normal rabbit serum. The
supernatant was aspirated, and the radioactivity in the pellet was
determined by a gamma counter.
Western Blot
To perform protein extraction, we thawed and homogenized frozen
lungs or cells in three volumes of lysis buffer [10 mM Tris (pH 7.4),
150 mM NaCl, 1% Triton X-100, 1% sodium deoxicolate, 0.1% SDS,
and 5 mM EDTA] containing a protease inhibitor cocktail, using a
Polytron homogenizer. The homogenate was clarified by centrifuga-
tion, and the final protein concentration was determined. Forty mi-
crograms of protein per sample were heated at 70°C for 10 min and
then electophoretically separated in a gradient NuPage 4–12% Bis-
Tris gel (Invitrogen) for 30 min under reducing (5% 2-mercaptoetha-
nol) conditions. Transfer blotting onto polyvinylidene difluoride
membranes was accomplished at 30 V for 1 h. Membranes were
subsequently blocked in 5% defatted milk-PBS for 1 h and incubated
overnight at 4°C with a primary rabbit antiserum directed to the
synthetic peptide P072 (amidated ADM22–52) diluted 1:1,000 or with
a mouse anti-	-actin antibody (Sigma) diluted 1:5,000. Characteriza-
tion of the anti-ADM antiserum was reported previously (22). Blots
were then incubated with the correspondent horseradish peroxidase-
linked secondary antibodies (1:5,000; Amersham Pharmacia Biotech)
and developed with Western blot Luminol Reagent kit (Santa Cruz
Biotechnology, Santa Cruz, CA). 	-Actin-immunoreactive bands
were used as an internal loading control. Adsorption controls for
ADM were performed using the ADM antiserum at 1:1,000 preincu-
bated with 10 M of amidated ADM22–52 (4°C overnight).
Statistical Methods
For each time point, the experimental design (LPS being present or
absent and normoxia or hypoxia) conformed to a 2  2 table, and
these data were analyzed by a two-way ANOVA, if the hypotheses of
normality and equal variance were rejected, to investigate the possible
interactions (synergism) between both factors: hypoxia and LPS. If
interactions between the concentration of oxygen and LPS treatment
were found, nonorthogonal comparisons with the Bonferroni adjust-
ment were performed. Because animals died after 24 h in the hyp-
oxia  LPS treatment, data were analyzed by one-way ANOVA for
this time point. Similarly, if the hypothesis of homogeneity of vari-
ances was rejected, one-way ANOVA with factorial treatments was
applied (SPSS, Chicago, IL). Values are expressed as the means 

SD, and statistical significance was defined as P  0.05.
RESULTS
In Vivo Model
Assessment of lung permeability to protein after differ-
ent treatments. To determine whether treatments of hypoxia,
LPS, or hypoxia  LPS induced pulmonary vascular injury,
extravasation of intravascular protein was measured with
FITC-labeled BSA. Compared with the control group, the
permeability index was found to increase significantly only
after the hypoxia  LPS treatment (3.75 
 0.31, n  4 vs.
5.57 
 1.2, n  4, respectively; P  0.0034). Immunohisto-
chemical detection of FITC in lung sections revealed weak
positivity in rat lungs treated with hypoxia or LPS alone (Fig.
1, B and C). However, FITC immunostaining was greatly
increased in the perivascular space and in alveolar macro-
phages of lungs from animals treated with hypoxia  LPS
(Fig. 1, D–F). Therefore, in contrast to the other experimental
conditions, only the hypoxia  LPS treatment seems to induce
pulmonary vascular injury as determined by extravasation of
albumin results.
ADM mRNA levels in rat lungs. Northern analysis for ADM
expression in rat lung demonstrated a consistent increase in its
mRNA induced by hypoxia, LPS, and hypoxia  LPS treat-
ments (Fig. 2). A synergistic effect in the upregulation of ADM
mRNA could be observed between hypoxia and LPS, with a
significant increase in the expression of ADM mRNA in lungs
of rats exposed to the combined treatment compared with the
expression after each treatment alone (Fig. 2A). This interac-
tion (synergism) in the combined treatment was found to be
statistically significant at 6 (P  0.003) and 12 (P  0.001) h
of treatment.
ISH on lung sections from control animals showed expres-
sion of ADM mRNA in some epithelial cells of bronchioles,
the endothelium of blood vessels, some cells of the lung
parenchyma, and in alveolar macrophages (Fig. 3, A–C). After
hypoxic exposure alone, there was an increase in the number of
positive bronchiolar cells and cells of the lung parenchyma,
and endothelial cells showed a more intense staining (Fig. 3,
D–F). In LPS-treated rat lungs (Fig. 3, G–I), ADM mRNA
expression was found only in inflammatory cells adhering to
vascular endothelial cells (Fig. 3I). The combined treatment
with hypoxia  LPS (Fig. 3, J–L) caused the highest expres-
sion of ADM mRNA, which was localized in bronchiolar
epithelial cells, inflammatory-like cells present in blood ves-
sels, and in most cells of the lung parenchyma (Fig. 3K).
Absence of staining using the sense riboprobe demonstrated
the specificity of the technique (Figs. 4, A and B).
ADM protein expression. Western blot analysis of rat lung
extracts revealed five immunoreactive bands for ADM and its
precursor species with approximate molecular masses of 22,
18, 15, 13, and 6 kDa (Fig. 4C), as described previously (15).
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Only the 6-kDa band, corresponding to the fully processed
ADM, changed its intensity along with the different treatments,
while the area and intensity of the rest of the immunoreactive
bands remained constant. Therefore, we focused our analysis
on the changes observed for the fully processed ADM peptide.
Adsorption controls of the antiserum against ADM with the
amidated ADM22–52 peptide showed no immunoreactive bands
(Fig. 4C).
Hypoxia and LPS treatments alone elicited an increase in
ADM expression compared with the signal in the control group
(Fig. 5). In accordance with the Northern blot results, the
combined treatment of hypoxia and LPS further increased
ADM production compared with either treatment alone, sug-
gesting a synergistic interaction of both treatments (Fig. 5). In
fact, a significant interaction between LPS and oxygen con-
centration was found at 3 (P  0.001), 6 (P  0.009), and 12
(P  0.036) h of treatment.
In Vitro Model
ADM expression in cell lines. Rat lung type II epithelial cells
(CCL-149), RPMVEC, and rat alveolar macrophages (CRL-
2192) were exposed to normoxia or hypoxia for 0.5, 1, 3, 6, 12,
or 24 h (Northern blot analysis) or 12, 24, or 48 h (RIA of the
conditioned medium) and concomitantly treated with or with-
out LPS. The study of ADM mRNA expression (Northern blot)
and secreted peptide (RIA) revealed different responses ac-
cording to cell type. Epithelial (Fig. 6) and endothelial (Fig. 7)
cell lines developed a similar pattern of ADM expression and
secretion in response to the treatments. Treatment with LPS in
normoxic conditions in these two cell types did not signifi-
cantly modify ADM expression and secretion compared with
the control group (Figs. 6 and 7). However, hypoxia and
hypoxia  LPS treatments resulted in an equivalent and strong
induction of ADM gene expression and secretion into the
conditioned media in both cell types.
Fig. 1. Permeability to albumin was assessed by immunolocalization of FITC. In control lungs (A), no detectable immunostaining for FITC is found. In rat lungs
treated with hypoxia (B) or LPS (C), slight immunoreactivity is observed in the perivascular space (arrows). After the hypoxia  LPS treatment (D–F),
FITC-albumin is highly accumulated in the perivascular space (D) and phagocyted by alveolar macrophages (E and F). Bars: 30 m (A–E), 6 m (F).
Fig. 2. Northern blot analysis of adrenomedullin (ADM) in rat lungs. A:
representative Northern blot analysis of ADM and S9 mRNA from lung
extracts of rats exposed to normoxia (20% O2) or hypoxia (9% O2) and injected
with saline or LPS (0.1 mg/kg) for 3, 6, 12, and 24 h. Combined treatment of
hypoxia and LPS was lethal at 24 h of exposure. Fifteen micrograms of total
RNA were loaded per lane. B: quantitation of ADM mRNA levels normalized
to the signal for S9 mRNA. To standardize between experiments, we assigned
an arbitrary density of 1 to the band obtained from lungs of rats exposed to
normoxia. Values are expressed as means 
 SD (bars) (n  4 for each group
at each time point). **P  0.01 compared with the control group; †P  0.05,
††P  0.01 compared with the hypoxia  LPS group.
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In the rat alveolar macrophage cell line, ADM mRNA signal
was barely detectable in cells exposed to normoxia or hypoxia
(Fig. 8A). However, treatment with LPS resulted in a signifi-
cant induction of ADM gene expression, which was further
increased with the combined treatment of hypoxia LPS (Fig.
8, A and B). Nevertheless, very low levels of secreted ADM in
the culture media were found by RIA analyses, with no
significant differences between groups (Fig. 8C). To explore
possible causes for the low ADM secretion levels in this cell
line, we performed experiments based on the addition of
exogenous ADM to the conditioned media with or without
protease inhibitors (5 mM EDTA and 0.5 mM 1,10 phenanth-
roline). Data in Fig. 8D suggest that ADM is being degraded in
the conditioned media of macrophages exposed to the four
experimental groups. Compared with the control group, the
degradation rate of ADM was greater in the hypoxia, LPS, and
hypoxia  LPS groups and was prevented by the addition of
EDTA or 1,10 phenanthroline (Fig. 8D). Although direct
addition of 1,10 phenanthroline to the macrophages at the
beginning of the experimental treatments considerably affected
cell viability (cell death 40 
 5%), secreted ADM was detect-
able in all the conditioned media, with the hypoxia  LPS
treatment showing a significant increase compared with the
control group (Fig. 8E).
DISCUSSION
The pathological features used to characterize ALI and
ARDS are increased permeability of the alveolar capillary
membrane, accumulation of edema, and severe hypoxemia (2).
This pathological process is typically described through three
overlapping phases (40). The acute (inflammatory) phase (usu-
ally develops the first week after the onset of the disorder) is
characterized by a rise in permeability of the alveolar-capillary
barrier and the influx of protein-rich edema. There is also an
increase in margination of pulmonary leukocytes, which to-
gether with alveolar macrophages, secrete numerous pro- and
anti-inflammatory mediators. The acute phase is followed by
the proliferative stage, which is essentially characterized se-
quentially by organization of exudates and fibrosis of the
alveolar spaces. Finally, in the fibrotic phase there is progres-
sion of the fibrotic lung injury, which involves the reduction of
lung compliance and impaired gas exchange. As previously
described (1), histological examination of the present rat model
showed a considerable rise in the number of inflammatory cells
(monocytes, neutrophils, and lymphocytes) migrating to the
lung in LPS-treated rats compared with rats treated with
normoxia or hypoxia. The number of inflammatory cells was
further increased when treatment with LPS was combined with
Fig. 3. In situ hybridization (ISH) for ADM mRNA in rat lungs after 3 h of treatment. ISH performed with the antisense riboprobe in normoxia-treated rat lungs
(A–C) shows expression of ADM mRNA in the apical region of some epithelial cells of bronchioles (arrow, A), alveolar macrophages (arrowhead, A), some cells
of lung parenchyma (B), and endothelium of blood vessels (C). In hypoxia-treated lungs, ADM mRNA is strongly expressed in most bronchiolar epithelial cells
(D), and in higher numbers of parenchymal (E) and endothelial cells (arrows, D and F) than in control lungs. After LPS treatment (G–I), no differences are found
with respect to the control group in bronchioles (G) and parenchyma (H), although numerous positive cells are found within blood vessels, most of which adhered
to the endothelium (arrows, I). In hypoxia  LPS-treated lungs (J–L), ISH with the antisense riboprobe shows an important increase of ADM mRNA expression
in bronchiolar (J) and parenchymal (arrows, K) cells. Additionally, numerous positive cells are found within blood vessels (arrows, L). Bar  30 m
(magnification is equivalent for every micrograph in Fig. 4).
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the concomitant exposure to hypoxia. In addition, the combi-
nation of hypoxia and LPS treatments was also characterized
by a significant increase in wet-to-dry lung weight ratio com-
pared with the other experimental conditions, which is consis-
tent with the pulmonary vascular injury observed in clinical
ALI (1). The present data on extravasation of FITC-albumin
shown both by permeability index determination and by im-
munocytochemical localization of FITC add further evidence
to support the relevance of the hypoxia  LPS treatment as a
good experimental model that seems to mimic the acute (in-
flammatory) phase of ALI.
Various studies have demonstrated elevated plasma levels of
ADM in animal models of ALI and in patients with SIRS (20).
In these studies, plasma ADM levels positively correlated with
the severity of ARDS (39). The increased production and
release of ADM in ARDS and other stress-associated pathol-
ogies have been considered as having a protective role during
the inflammatory response (7). In relation to this, Shindo et al.
(34), using transgenic mice overexpressing ADM in their
vasculature, have demonstrated the protective role of ADM
against circulatory collapse, organ damage, and mortality char-
acteristic of endotoxic shock. Furthermore, the combined ad-
ministration of ADM and the complement component factor H,
an ADM binding protein, attenuated tissue injury and reduced
the mortality rate in the cecal ligation and puncture rat model
of sepsis (42). Specifically, in experimental ALI/ARDS con-
ditions, elevated plasma and lung levels of ADM have been
proposed to perform its beneficial role mainly by two comple-
mentary mechanisms: firstly, reducing endothelial hyperper-
meability by cAMP-dependent relaxation of the endothelial
microfilament system and thus reducing edema formation (11),
and secondly, ensuring myocardial performance through its
vasodilatory effects counteracting those of endothelin-1 from
the lung (36).
ADM has been found to be upregulated by hypoxia and LPS,
two key factors involved in ALI, both in vivo (12) and in vitro
(26). In the present work we have analyzed the expression of
ADM by a variety of biochemical and molecular techniques in
a rat experimental model of ALI that combines hypoxia and
LPS stimuli. In parallel, we have performed in situ techniques
to identify which cell types in the lung are involved in the
synthesis and release of ADM. Our results show that acute
hypoxia and LPS treatments alone induce ADM expression
(mRNA and protein) in rat lung as reported previously (12, 24).
ISH techniques in the lungs of rats exposed to hypoxia showed
that, apart from endothelial cells (41), upregulation of ADM
mRNA is further localized in epithelial cells of bronchioles and
cells in the parenchyma. In the LPS-treated group, besides
endothelial cells (24), a large number of inflammatory cells
within blood vessels are the main source of ADM mRNA
overexpression. Interestingly, when hypoxia and LPS stimuli
Fig. 5. Western blot for lung mature ADM expression. A: representative
immunoblot of lung fully processed ADM (6 kDa band) and 	-actin protein
content of normoxic and hypoxic rats injected with saline or LPS (0.1 mg/kg)
for 3, 6, and 12 h. B: densitometric analysis of ADM expression (6-kDa band)
with different treatment and times of exposure is shown as the ratio of ADM
to 	-actin signals for each sample. An arbitrary density of 1 was assigned to
the band obtained from lungs of rats exposed to normoxia (N) to standardize
between experiments. Data shown as means
 SD (bars) (n 4 for each group
at each time point) *P  0.05, **P  0.01 compared with the control group;
††P  0.01 compared with the hypoxia  LPS group.
Fig. 4. Negative controls for ISH and Western blot techniques. Serial sections
of rat lung treated with hypoxia  LPS for 3 h and hybridized with the
antisense (A) or sense (B) riboprobe for rat ADM. Note the absence of labeling
when hybridization is performed with the sense riboprobe. Bar  30 m. C:
Western blot for ADM in homogenates of rat lungs treated with hypoxia 
LPS for 6 h. Five ADM-immunoreactive bands, including the mature peptide
(6 kDa) can be observed. Adsorption control (ADS) lacks immunoreactivity.
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are combined, ADM expression (mRNA and protein) is syn-
ergistically induced in rat lungs. As demonstrated by ISH in the
combined treatment, the cells mostly responsible for this in-
crease in ADM mRNA expression in the lungs are numerous
inflammatory cells within blood vessels; to a lesser extent, also
cells and in the lung parenchyma and epithelial cells in bron-
chioles and alveoli account for the upregulated ADM synthe-
sis. Our results demonstrate that ADM is greatly overexpressed
in this experimental model of the inflammatory phase of ALI,
suggesting that this peptide may play a relevant role in this
syndrome, although more studies are needed to describe the
precise role of ADM in ALI. Moreover, our data point to the
lungs as a likely contributing source of the elevated ADM
plasma levels occurring in ALI patients.
ADM biology is closely related to nitric oxide synthase-2
(NOS2) and the NO cascade. NO has been shown to stimulate
ADM production in endothelial and smooth muscle cell lines
(6, 13). Furthermore, in transgenic mice overexpressing ADM
in their vasculature, NO production is highly augmented (34).
Both ADM and NO share diverse physiological functions that
Fig. 6. Expression of ADM in the CCL-149
epithelial cell line. A: representative Northern
blot analysis for ADM mRNA expression. B:
relative ADM mRNA expression after 12 h of
treatment normalizing ADM densitometric val-
ues to those of S9 for each sample. Standardiza-
tion between experiments was accomplished as-
signing an arbitrary density of 1 to the signal
obtained from cells exposed to normoxia. N,
normoxia; H, hypoxia. C: ADM peptide in the
conditioned media measured by RIA. Values are
expressed as means 
 SD (bars) (n  3 for each
group). *P  0.05, **P  0.01 compared with
the control group; ††P  0.01 compared with
the hypoxia  LPS group.
Fig. 7. Expression of ADM in the RPMVEC
endothelial cell line. A: representative Northern
blot analysis for ADM mRNA. B: relative ADM
mRNA expression after 12 h of treatment ex-
pressed as the ratio of ADM to S9 mRNA
densitometric values. To standardize between
experiments, an arbitrary density of 1 was as-
signed to the band obtained from cells exposed
to normoxia. C: ADM peptide in the conditioned
media by RIA analysis. Values are expressed as
means 
 SD (bars) (n  3 for each group).
*P  0.05, **P  0.01 compared with the
control group; ††P  0.01 compared with the
hypoxia  LPS group.
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include vasodilation, bronchodilation, and antimicrobial activ-
ity. A previous study from our laboratory reported an increase
in the expression of NOS2 in the present model of ALI and the
involvement of inflammatory cells in this event (1). In this
animal model of ALI, ADM and NO appear to be upregulated
in a coordinated fashion that may possibly be related to a
cooperative role in the control of the inflammatory response.
In accordance with the animal model, a differential regula-
tion of ADM expression in the three rat lung cell types studied
(endothelial, type II epithelial cells, and alveolar macrophages)
was found in our in vitro studies. Endothelial and epithelial
cells showed basal detectable levels of ADM (mRNA and
protein) in normoxic conditions. In the same way, ADM
expression had been observed previously in endothelial cells
from different species and types of blood vessels (26, 37).
Also, ADM and its receptor L1 have been found in human type
II pneumocytes (21) and have been correlated with increased
secretion of phosphatidylcholine, the predominant component
of pulmonary surfactant (31). After LPS treatment, ADM
expression in epithelial and endothelial cells was similar to that
in the control group. In the type II epithelial cell line (CCL-
149), this finding was not surprising since we did not find
expression of Toll-like receptor 4 (TLR4), the main receptor of
LPS by RT-PCR techniques (data not shown). Concerning the
endothelial RPMVEC cells, previous studies report that ADM
expression in endothelial cells in response to LPS varies
greatly in endothelial cells from different origins (37). Al-
though RPMVEC express TLR4 mRNA (RT-PCR data not
shown), it has been previously reported that a combination of
LPS and cytokines is needed to induce NOS2 expression in this
cell line (43). It is probable, therefore, that combination of LPS
with other stimuli might also be needed for ADM induction in
RPMVEC. Concerning hypoxic conditions, a clear induction of
ADM expression and secretion was found in the epithelial and
endothelial cell lines studied herein, as we and others previ-
ously reported in epithelial cells from different sources (8, 38)
and endothelial cells (26). When we subjected epithelial and
endothelial cells to a combined treatment of hypoxia and LPS,
the expression and secretion of ADM were similar to that
obtained after exposure to hypoxia alone. This seems to cor-
relate with the absence of ADM induction by treatment with
LPS, indicating that in both cell lines, only the hypoxic
stimulus induces the expression and secretion of ADM.
Other authors have shown basal ADM gene expression and
release in macrophages and their related cells (18, 27), partic-
ularly in alveolar macrophages (28). In the present study, the
Fig. 8. Expression of ADM in the CRL-2192
alveolar macrophage cell line. A: representative
Northern blot analysis for ADM. B: relative
ADM mRNA expression after 12 h of treatment
as the ratio of ADM to S9 mRNA densitometric
values. To standardize between experiments, an
arbitrary density of 1 was assigned to the value
correspondent to cells exposed to normoxia. C:
rat ADM peptide in the conditioned media by
RIA analysis. D: ADM concentration was as-
sessed by RIA analysis. The conditioned media
of macrophages exposed to 24 h of treatment
were incubated with exogenously added ADM
(1.28 ng/ml) for 24 h at 37°C, together with 5
mM EDTA (dark gray bars) or 0.5 mM 1,10
phenanthroline (Phen., open bars) or absence of
protease inhibitors (closed bars). Initial ADM
content in the conditioned media (previous to
ADM addition) is represented as light gray bars.
E: RIA analysis of rat ADM in the conditioned
media of macrophages treated with (open bars)
or without (closed bars) 0.5 mM 1,10 Phen. at
the beginning of a 24-h exposure to each exper-
imental condition. Values are expressed as
means 
 SD (bars) (n  3 for each group).
*P  0.05, **P  0.01 compared with the
normoxia group; ††P  0.01 compared with the
hypoxia  LPS group.
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expression of ADM mRNA in the rat alveolar macrophage cell
line (CRL-2192) after hypoxic exposure was similar to that in
normoxic conditions, although a great overexpression of ADM
transcripts was assessed after LPS treatment. The stimulatory
effect of LPS on ADM expression and secretion has also been
observed in monocyte-derived macrophages and in the mouse
peritoneal macrophage-derived RAW 264.7 cell line (18, 27).
On the other hand, in relation to hypoxic stimulation and in
agreement with our results, it has been reported that hypoxic
exposure alone does not induce ADM expression in human
peritoneal macrophages unless proceeding from cirrhotic pa-
tients (4). After the simultaneous exposure to hypoxia and LPS,
we found that ADM mRNA expression was even greater than
in macrophages treated with LPS and exposed to normoxia,
showing a synergistic effect between both stimuli. Despite this,
RIA analyses of conditioned media from the CRL-2192 cell
line showed no differences in the secretion of ADM peptide
among the four experimental groups. In this regard, degrada-
tion of exogenously added ADM has been reported when
incubated with lung, adrenal, and kidney tissue extracts (19).
Besides, this degradation was prevented by addition of EDTA
or phenanthroline (19) [a selective inhibitor of metalloprotein-
ases (MP) (33)]. Moreover, it is also known that rat alveolar
macrophages produce a wide spectrum of MP (9) and that
exposure to different stimuli such as hypoxia (3) or LPS (9)
upregulates the expression of MP in this cell type. This back-
ground led us to design different experiments to test the
hypothesis that secreted ADM was being degraded in the
culture media by the parallelly secreted MP. This hypothesis
was corroborated since exogenously added ADM degradation
was mainly shown after hypoxia, LPS, and hypoxia  LPS
treatments, and ADM degradation could be prevented by the
addition of protease inhibitors (EDTA and phenanthroline) to
the culture media (Fig. 8, D and E). Moreover, although cell
viability was compromised, when phenanthroline was directly
added to CRL-2192 cells, ADM degradation could be partially
abrogated, and a significant increase in ADM in the culture
medium was found after the combined treatment compared
with the control group. The present study demonstrates that in
rat alveolar macrophages, the combined treatment of hypoxia
and LPS greatly induces the expression of ADM mRNA as
well as the secretion of the mature peptide, thus paralleling the
synergistic interaction of both factors observed in the in vivo
model. This response in alveolar macrophages is presumably
mediated by the hypoxia inducible transcription factor-1,
which has been found to be essential in macrophage response
to hypoxia and inflammation (5). Further studies are needed to
elucidate whether the ADM secreted by alveolar macrophages
might subsequently be degraded by concomitantly secreted MP
in ALI conditions. One might as well hypothesize that ADM
peptide degradation by macrophage-derived proteases could
also constitute a mechanism to regulate ADM levels, since the
lung has been shown to be the main clearance organ for this
peptide (29).
In summary, ADM expression is highly induced in the
present rat model of ALI that combines exposure to hypoxia
and treatment with LPS. In addition, there is a good correspon-
dence between our findings in the in vitro experiments and the
data obtained in the in vivo model. In this regard, hypoxic
exposure induces ADM expression in endothelial and epithelial
cells in both models, whereas LPS treatment per se does not
have any inductor effect on ADM production in these cell
types. In response to the hypoxia  LPS combined treatment,
ADM expression is induced in a variety of key cell types such
as alveolar macrophages and endothelial and epithelial cells,
although the effects in other cell types, such as other inflam-
matory cells and type I pneumocytes, deserves further in vitro
studies.
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